Introduction
For years, biosimilars sat in a strange spot in the regulatory conversation: clearly important, frequently discussed at conferences, but not yet a major hiring category on their own. That's shifted. As more originator biologics lose exclusivity and more companies build out biosimilar-specific pipelines, regulatory affairs job postings increasingly ask for experience with biosimilar development pathways specifically, not just "biologics" experience in general. This article looks at why biosimilar regulatory work has become its own hiring lane, what makes it different from originator biologic or small molecule regulatory work, and what professionals interested in this space should understand before pursuing it.
Why Biosimilars Need a Different Regulatory Skill Set
The core difference between originator and biosimilar regulatory strategy comes down to what each pathway is trying to prove. An originator biologic submission builds the case for safety and efficacy essentially from scratch, supported by a full clinical development program. A biosimilar submission instead builds a case for similarity to an already-approved reference product, relying heavily on analytical comparability data, with a more targeted clinical program focused on confirming that similarity rather than establishing efficacy independently. That shift in the underlying scientific argument changes what a regulatory professional actually spends their time doing.
Biosimilar regulatory work leans heavily on analytical and CMC comparability: structural characterization, functional assays, and pharmacokinetic bridging studies that demonstrate the biosimilar behaves the same way as the reference product. Regulatory professionals in this space need to be comfortable reading and interpreting dense analytical data packages and translating that into a submission narrative that satisfies a health authority's totality-of-evidence review, a concept that both FDA and EMA use but apply with their own particular expectations and precedent. That's a meaningfully different day-to-day skill set than pure clinical regulatory strategy work, and it's part of why companies building biosimilar pipelines are increasingly specific in job postings about wanting candidates with direct comparability or analytical submission experience.
Interchangeability Adds Another Layer in the US
In the United States, biosimilar regulatory strategy carries an additional wrinkle that doesn't exist in most other regulatory work: the interchangeability designation. A biosimilar approved without interchangeability can still be prescribed, but a pharmacist generally cannot substitute it for the reference product without the prescriber's involvement, depending on state law. An interchangeable biosimilar can be substituted at the pharmacy level in states that allow it, similar to how a generic small molecule drug is substituted today. Pursuing interchangeability historically required additional switching studies, though FDA's expectations here have evolved over time and companies now weigh whether the additional investment is worth the commercial upside for a given product.
Regulatory professionals working in biosimilars need to understand this distinction well enough to help shape that strategic decision early, since the interchangeability pathway affects clinical trial design, timeline, and cost. It's a genuinely US-specific piece of the puzzle, since the European Medicines Agency and most other major regulators treat all approved biosimilars as automatically substitutable in ways governed by national rather than EU-level rules, meaning global regulatory strategists need to hold two different frameworks in their head simultaneously when planning a multi-region filing.
Patent and Exclusivity Timing Shapes the Regulatory Calendar
Unlike most regulatory work, biosimilar submission timing is driven as much by patent and exclusivity landscapes as it is by clinical readiness. Companies developing biosimilars track originator patent expiration dates, settlement agreements, and exclusivity periods closely, because filing too early accomplishes little if patent litigation blocks launch, and filing too late cedes market share to faster-moving competitors targeting the same reference product. Regulatory affairs professionals in this space often work closely with intellectual property and legal teams in a way that's less central to originator drug regulatory work, tracking the so-called "patent dance" process under the Biologics Price Competition and Innovation Act and factoring litigation risk into submission timing recommendations.
This adds a layer of commercial and legal fluency to the role that some regulatory professionals find genuinely engaging, since it makes the regulatory strategy conversation less purely scientific and more tied to overall business strategy. For companies, it also means they're looking for regulatory hires who can hold a cross-functional conversation with legal and commercial teams comfortably, not just clinical and CMC.
Where the Roles Are Concentrated
Biosimilar regulatory hiring isn't evenly spread across the industry. It concentrates most heavily at companies with dedicated biosimilar development units, which include several large originator biologic manufacturers that have built parallel biosimilar businesses, a growing number of specialty biosimilar-focused companies, and generic drug manufacturers that have expanded into biologics as their small molecule portfolios matured. Contract development and manufacturing organizations supporting biosimilar analytical work have also expanded their regulatory affairs teams, since comparability testing is such a central part of the submission package.
Geographically, hiring activity tracks the regions with the most mature biosimilar approval pathways and reimbursement systems, meaning the United States and European Union remain the deepest markets for these roles, though activity in other regions with maturing biosimilar frameworks continues to grow as more health systems build out substitution and reimbursement policy for these products.
Global Pathways Aren't Uniform
Part of what makes biosimilar regulatory strategy demanding is that the underlying scientific concept, biosimilarity through comparability, is applied with real differences from one health authority to the next. The World Health Organization published early guidance that shaped how many national regulators approached biosimilars, but individual agencies have since built their own frameworks with their own expectations around reference product sourcing, the extent of clinical bridging data required, and how switching studies are evaluated. A regulatory professional building a global biosimilar filing strategy needs to track which markets will accept data generated against a reference product sourced from another region, since some agencies require local reference product comparability data while others accept bridging arguments based on a global reference product. Getting this wrong doesn't just create rework, it can add a full clinical bridging study to a program's timeline and budget.
This regional variation is one more reason biosimilar regulatory strategy tends to reward professionals who enjoy tracking regulatory intelligence closely rather than working from a fixed playbook. Agency thinking on biosimilars has continued to evolve as more products reach the market and more real-world safety and interchangeability data accumulates, so guidance that was current three or four years ago may no longer reflect how a given authority actually reviews a submission today.
Building Toward This Niche Deliberately
For regulatory professionals who want to move into biosimilar work rather than falling into it, a few moves tend to help. Seeking out CMC-adjacent project assignments, even informally, builds the comparability fluency that hiring managers screen for. Reading published biosimilar approval summaries and complete response letters where available is a genuinely useful, low-cost way to see how agencies have reasoned through real comparability arguments, since these documents often spell out exactly what evidence tipped a review one way or another. And building familiarity with the patent and exclusivity landscape for a therapeutic class of interest, even at a basic level, signals to hiring managers that a candidate understands the business context the role sits inside, not just the science.
Professional organizations including RAPS and DIA have expanded their biosimilar-specific programming over the past several years, reflecting the same hiring shift described here, and attending or following that programming is a reasonably direct way to build both knowledge and a network in the space before actively job hunting.
What Hiring Managers Actually Screen For
Job postings in this space tend to prioritize a few specific things over general biologics experience. Direct experience with a comparability protocol or analytical similarity assessment carries real weight, even if that experience came from a CMC-adjacent role rather than a pure regulatory one, since the skill of interpreting and presenting that data translates directly. Familiarity with FDA's biosimilar guidance documents and EMA's biosimilar guideline, along with a working understanding of how each authority's totality-of-evidence framework is applied in practice, matters more here than in general regulatory hiring, since the whole submission strategy hinges on that concept. And for US-focused roles, direct exposure to an interchangeability submission or even involvement in the strategic decision of whether to pursue one is increasingly called out explicitly.
For professionals without direct biosimilar experience but with strong CMC or analytical regulatory backgrounds, this is a genuinely reachable niche to move into, since the underlying skills, careful data interpretation, comparability thinking, and cross-functional coordination, transfer well. The clearest path in tends to be through CMC-focused regulatory roles at companies with biosimilar programs, where exposure to comparability work happens naturally even before a formal title change.
Conclusion
Biosimilars have moved from a niche topic at regulatory conferences to a genuine, identifiable hiring category with its own required skills: analytical comparability fluency, familiarity with the interchangeability pathway in the US, and comfort working alongside legal and commercial teams on patent-driven timing decisions. For regulatory professionals with a CMC or analytical background, or for hiring managers building out biosimilar pipelines, understanding what actually separates this work from originator biologic regulatory strategy is the first step to hiring, or being hired, well in this growing corner of the field.